PACS Group, Inc.
No SEC Form 4 filings for $PACS in the last 30 days.
PACS Group, Inc.'s Chief Legal Officer & Secretary, John Todd Mitchell, sold 80,152 shares of common stock in open-market transactions on May 15 and May 18, 2026. These sales, totaling over $3 million, were executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Mitchell still holds more than 800,000 PACS shares directly.
PACS Group, a major U.S. post-acute healthcare company, reported a significant increase in its first-quarter 2026 net income, up 184.2% to $80.7 million, with revenue reaching $1.42 billion. Following this strong financial performance, the company's Board of Directors approved a $250 million share repurchase authorization. PACS also raised its full-year 2026 Adjusted EBITDA guidance to a range of $605 million to $625 million, demonstrating confidence in its continued growth and operational efficiency.
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into PACS Group, Inc. (NYSE:PACS) regarding potential corporate wrongdoing involving its officers and/or directors. The firm is encouraging investors who purchased PACS securities before April 11, 2024, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, representing investors injured by securities fraud and aiming to restore investor capital and ensure corporate accountability.
